Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Minerva Neurosciences is a small drug company trying to win approval for one medicine that treats schizophrenia.
Minerva Neurosciences is a small biotech company with a single big bet. It develops drugs for brain and nervous system disorders, and its whole future rests mostly on one experimental medicine called roluperidone, a pill intended to treat schizophrenia. The company is based in Burlington, Massachusetts, just outside Boston, a region packed with drug research talent.
Here is the problem it is trying to solve. People with schizophrenia often hear voices, feel paranoid, and struggle to think clearly. Existing antipsychotic drugs can quiet the hallucinations, but they often do little for the "negative" symptoms — the flat emotions, the withdrawal, the trouble with motivation and clear thinking — that make it hard to hold a job or keep friendships. Roluperidone is aimed squarely at those negative symptoms and at cognitive problems, not the hallucinations. If it works, it would fill a gap that big drugmakers have largely left open. The company does not sell anything yet. It has no approved product and no meaningful revenue from customers; it survives on cash raised from investors and, at times, from partners. Minerva has burned through years of clinical trials, and roluperidone's path has been rocky. The U.S. Food and Drug Administration has twice declined to accept the company's application for approval, and Minerva has had to run additional work and push back its timeline. That regulatory fight is the central drama of the business — approval would turn a money-losing lab project into an actual product, while another rejection would be a serious blow.
For investors, this is a high-risk, binary story. The stock rises and falls on trial results and FDA decisions rather than on sales trends, because there are no sales yet. Minerva's cash position matters enormously, since it must fund trials and regulatory work without product income, and it has leaned on outside financing to stay alive. If roluperidone eventually wins approval, the company would need a partner or its own sales effort to reach psychiatrists and patients. Until then, Minerva is a company selling a promise rather than a product.
Saved answer · last researched 15 Nov 2026